1 day Ago By ABMN Staff
I-Mab ( NASDAQ:IMAB – Get Free Report ) ‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They presently have a $8.00 price target on the stock.
I-Mab Price Performance Shares of I-Mab stock opened at $1.09 on Tuesday. The company has a 50-day simple moving average of $1.
23 and a two-hundred day simple moving average of $1.58. I-Mab has a 52-week low of $0.
99 and a 52-week high of $2.54. I-Mab ( NASDAQ:IMAB – Get Free Report ) last released its quarterly earnings data on Wednesday, August 28th.
The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.
44. As a group, analysts anticipate that I-Mab will post -0.38 earnings per share for the current fiscal year.
Hedge Funds Weigh In On I-Mab I-Mab Company Profile ( Get Free Report ) I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Featured Stories Receive News & Ratings for I-Mab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for I-Mab and related companies with MarketBeat.
com's FREE daily email newsletter ..
